Denosumab is used for fracture prevention in which condition?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Study for the Foundation Year Pharmacy – Clinical Practice Test. Prepare with detailed questions, step-by-step explanations, and test format insights. Enhance your readiness and confidence!

Multiple Choice

Denosumab is used for fracture prevention in which condition?

Explanation:
Denosumab works by blocking RANKL, a signal essential for osteoclast formation and bone resorption. By inhibiting RANKL, it reduces bone breakdown, helping to increase bone density and lower fracture risk. This makes it a key option for fracture prevention in osteoporosis, a condition characterized by low bone mass and weakened bone structure that leads to fragility fractures. The other conditions—osteoarthritis, gout, and osteopenia—do not involve this systemic overresorption that denosumab targets, so they are not the primary indications for fracture-prevention therapy with denosumab. Denosumab is given as a 60 mg subcutaneous injection every six months.

Denosumab works by blocking RANKL, a signal essential for osteoclast formation and bone resorption. By inhibiting RANKL, it reduces bone breakdown, helping to increase bone density and lower fracture risk. This makes it a key option for fracture prevention in osteoporosis, a condition characterized by low bone mass and weakened bone structure that leads to fragility fractures. The other conditions—osteoarthritis, gout, and osteopenia—do not involve this systemic overresorption that denosumab targets, so they are not the primary indications for fracture-prevention therapy with denosumab. Denosumab is given as a 60 mg subcutaneous injection every six months.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy